The $122 Billion Question: Can Clinical Trial Supply Systems Keep Pace With Cell Therapy Demand?

By Kien Tran, founder, KT Biosync Consulting

The stakes could not be higher.

An estimated 20% of patients eligible for FDA-approved CAR T cell therapies die awaiting treatment.¹ While we have witnessed remarkable scientific breakthroughs in cell therapy with treatments that can cure previously incurable cancers and genetic diseases, our manufacturing infrastructure simply has not kept pace.

The global cell and gene therapy market is projected to reach nearly $37 billion with a 46% compound annual growth rate over the next five years,² yet we are struggling to deliver these lifesaving therapies to the patients who need them most.

The solution? A manufacturing revolution powered by artificial intelligence and automation that is already transforming how we produce living drugs.

From a clinical trial supply perspective, this is not only a manufacturing scale problem. It is a patient-level supply continuity problem. Each delay or constraint in production directly translates into missed or shifted infusion windows, making manufacturing capacity a downstream determinant of clinical trial execution timelines.

The Manufacturing Capacity Crisis

Cell therapy manufacturing faces a perfect storm of challenges. Manufacturing remains a major challenge for the industry due to a lack of standardization, and scale-up has often been an obstacle to regulatory approval and commercialization.³ The numbers tell a sobering story: in Germany alone, annual demand for CAR T cells has quadrupled within four years, yet current manufacturing capacity serves less than 10% of eligible patients.⁴

The bottlenecks are multifaceted and interconnected. Research-grade equipment often lacks the automation and data integration necessary for commercial-scale applications, meaning if a process is built around manual instrumentation, scaling out requires a linear increase in facility size and headcount – a model that quickly becomes unsustainable.⁵

Fabian Gerlinghaus, CEO of Cellares, notes that "cell therapy is relatively new, and no one has been able to meet commercial demand, making it difficult to find enough people with hands-on cGMP and QC experience."⁶

Even seemingly mundane operational details become critical constraints at scale. Leela Paris of Aspect Biosystems cited a real-world example where gowning time became a bottleneck when scaling out: with each operator taking 20 minutes to gown, small gowning spaces accommodating only two or three people resulted in round-the-clock gowning activities.⁷

These constraints translate directly into clinical trial supply planning challenges, where manufacturing slot availability must be aligned with patient enrollment and apheresis scheduling. In practice, clinical supply teams must avoid triggering patient collections that cannot be processed within validated manufacturing windows, creating a tight dependency between site activation, IRT-driven patient scheduling, and manufacturing capacity allocation, where enrollment triggers must be aligned with available production slots to avoid initiating collections that cannot be fulfilled.

In operational terms, this means clinical supply teams must manage manufacturing capacity as a constrained, per-patient resource within IRT systems — embedding slot availability into enrollment logic to prevent protocol-compliant patients from entering the study when supply cannot be executed

Automation Success Stories: Proof Of Concept To Patient Impact

Against this backdrop, pioneering companies are demonstrating that automation can fundamentally transform cell therapy manufacturing economics and accessibility.

Cellares, positioning itself as the first integrated development and manufacturing organization, has developed the Cell Shuttle platform that delivers industry-leading manufacturing economics with the ability to produce up to 10 times more cell therapy batches than conventional CDMOs with comparable footprint and headcount.⁸ The company recently achieved a critical milestone: the first two patients were dosed with CAR-T therapy manufactured on their automated Cell Shuttle platform, demonstrating that automation can deliver GMP drug products on time and within specification at a scale and cost structure that makes therapies accessible for much larger patient populations.⁹ This was not just a technical achievement – it was validation that the path forward for cell therapy is industrial, with the potential to slash the capital and labor costs choking the field.¹⁰

Multiply Labs has developed robotic clusters that integrate industry-standard cell therapy manufacturing equipment. Proof-of-concept results published in early 2024 demonstrated that their self-contained system could produce cells with similar proliferation, viability, and genetic expression to manual culture, with the company now undergoing pilot studies for end-to-end automated production.¹¹

On the viral vector front – a critical enabler for many cell and gene therapies – Forge Biologics has made significant strides in scalability. The company has achieved scale-up to 200-liter serum-free suspension cultures on the lentiviral-vector side, with some discussing 500 or 1,000 liters, alongside perfusion processes.¹² Their custom-designed facility houses 20 cGMP suites with bioreactor capacity up to 5,000 liters, providing AAV production across every stage from research-grade to commercial manufacturing.¹³

From a clinical supply execution standpoint, these automation platforms shift the operating model from inventory forecasting to dynamic manufacturing slot allocation. Instead of building buffer stock at depots, supply teams increasingly coordinate patient demand against real-time production capacity, where each manufacturing slot effectively functions as a patient-specific supply reservation.

In practice, this creates a tightly coupled workflow: once a patient is enrolled and deemed eligible, a manufacturing slot must be reserved before apheresis is initiated. Collected cells are then shipped under chain-of-identity controls to the manufacturing site, where batch initiation is tied to that reserved slot. Following production and quality release, the final product is scheduled for return shipment and infusion within a defined viability window. Any delay at one step, whether in transport, manufacturing start time, or release testing, requires real-time rescheduling across the entire chain, often involving both clinical operations and supply teams.

Operationally, this requires clinical supply teams to run continuous cross-functional reconciliation loops — between IRT enrollment triggers, manufacturing execution systems (MES), and site readiness signals — to dynamically confirm slot viability, prevent out-of-window collections, and reallocate capacity in real time when disruptions occur. 

The AI Advantage: Intelligence Meets Manufacturing

The integration of artificial intelligence is accelerating these gains. The AI-powered cell and gene therapy manufacturing market, valued at $14.69 billion in 2025, is projected to exceed $122.86 billion by 2034, advancing at a robust 26.62% CAGR.¹⁴ The global automation, digitization and robotics in cell and gene therapy manufacturing market revenue surpassed $950 million in 2025 and is predicted to reach around $5.28 billion by 2035.¹⁵

What Is Driving This Explosive Growth?

AI-driven process control, high-throughput solutions for remote quality control testing using process analytical technologies, and real-time release testing capabilities are accelerating product release timelines while ensuring higher quality standards, directly addressing what has historically been one of the largest bottlenecks in CGT manufacturing.¹⁶

A unified digital layer can automate the entire end-to-end process, seamlessly capturing and controlling process logs, user actions, system states, and low-level sensor data ready for AI and machine learning-driven optimization.¹⁷

When integrated with clinical supply systems, these AI layers extend beyond manufacturing optimization into predictive supply orchestration, enabling earlier detection of potential delays in batch release and allowing downstream rescheduling of patient dosing events before disruptions occur.

For example, if release testing is delayed beyond the planned infusion window, the product may no longer meet viability constraints, forcing either re-manufacturing or patient rescheduling. In trials with limited manufacturing capacity, this can result in slot reallocation decisions where one patient’s delay impacts another’s ability to receive therapy, creating a cascading supply disruption across the study.

This is not futuristic speculation; it is happening now in operational facilities.

The Decentralized Revolution

Perhaps the most transformative trend is the shift toward point-of-care and decentralized manufacturing. In January 2025, the United Kingdom's MHRA implemented changes to drug regulations enabling decentralized manufacturing, creating new licenses for "modular manufacturing" and "Point of Care" production.¹⁸ The Alliance for Regenerative Medicine predicted that more than five new gene therapies would gain regulatory approval by the end of 2025, increasing demand for decentralized manufacturing capabilities.¹⁹

The clinical benefits are compelling. In a recent Phase 1 trial, CAR-T products were manufactured in just three days and administered within five days after apheresis; despite the short turnaround and reduced cell dose, patients who had previously failed CAR-T therapy showed a 52% response rate.²⁰ Academic institutions in middle-income countries like Mexico have successfully validated decentralized CD19 CAR-T manufacturing processes,²¹ demonstrating that this model can expand global access.

This decentralization fundamentally changes clinical trial supply architecture. Instead of centralized distribution to depots and sites, supply chains shift toward distributed manufacturing nodes embedded closer to treatment centers. This reduces transport complexity but increases dependency on site-level operational readiness, including QA oversight, equipment uptime, and real-time release authorization systems.

Critical Factors To Watch

As we look ahead, several factors will determine whether this manufacturing revolution fulfills its promise:

Regulatory Harmonization: While the EMA's new guideline on clinical-stage ATMPs effective July 1, 2025, demonstrates substantial alignment with FDA approaches, differences persist in areas such as donor eligibility determination and GMP compliance expectations.¹⁹ Global standardization will be essential for truly decentralized models.

Talent Development: The industry must urgently address the shortage of personnel with cGMP and quality control experience. As automated systems become more sophisticated, the workforce needs will shift from manual operators to specialists in process engineering, data analytics, and system integration.

Sustainability and Economics: Current CAR-T therapies cost between €200,000 and €250,000 per dose, with personnel costs, cleanroom infrastructure, and regulatory requirements being the main adjustable cost drivers.⁴ Automation promises to deliver the cost reductions necessary for broader patient access.

From a clinical supply standpoint, cost reduction will depend not only on manufacturing efficiency but on reducing operational waste in supply execution, such as avoiding expired product, minimizing resupply delays, and improving synchronization between production output and patient demand.

Expansion into New Indications: The field is rapidly moving beyond hematological malignancies. Success in solid tumors and autoimmune diseases – indications with far larger patient populations – will require manufacturing capacity that simply does not exist under current models.

The Path Forward: Collaboration As Imperative

The organizations that successfully navigate this dynamic landscape embracing automation, digital tools, and strategic partnerships will be best positioned to bring lifesaving therapies to patients at scale.¹⁶

This is not about any single company or technology; it is about an ecosystem transformation.

As cell therapy moves from scientific triumph to therapeutic reality, the manufacturing challenge is not just technical – it is a moral imperative.

Every percentage point improvement in manufacturing efficiency, every day shaved off production timelines, and every dollar reduced in cost of goods translates directly into more patients receiving potentially curative therapies. Critically, these gains only translate into patient impact when matched by equally mature clinical supply coordination systems capable of synchronizing enrollment, manufacturing, release testing, and site-level administration into a unified operational flow.

The tools are in our hands. Automated platforms are proving themselves in clinical production. AI is delivering real-time optimization. Regulatory frameworks are evolving to support innovation.

The question now is how quickly we can scale these solutions to meet the extraordinary demand. The lives of hundreds of thousands of patients depend on our answer.

References:

1. Pharma Manufacturing. "Cellares: A disruptive impact on cell therapy." https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/33037531/cellares-a-disruptive-impact-on-cell-therapy
2. Oliver Wyman. "Explore The Commercial Landscape Of Cell And Gene Therapies." May 2024. https://www.oliverwyman.com/our-expertise/insights/2024/may/commercial-viability-gap-in-cell-and-gene-therapy.html
3. Pharma Manufacturing. "Cell and gene therapy manufacturing challenges to persist in 2025." December 23, 2024. https://www.pharmamanufacturing.com/all-articles/article/55251398/cell-and-gene-therapy-manufacturing-challenges-to-persist-in-2025
4. Frontiers in Bioengineering and Biotechnology. "Industrializing CAR-T cell therapy: impact of automation on cost and space efficiency of manufacturing facilities." September 22, 2025. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1612248/full
5. Technology Networks. "Cell Therapy Manufacturing: Challenges and Innovation." February 25, 2026. https://www.technologynetworks.com/biopharma/articles/quality-compliance-and-scale-in-modern-cell-therapy-manufacturing-409442
6. BioSpectrum Asia. "Navigating, manufacturing, infrastructure & regulatory hurdles in CAR T-Cell therapy growth." October 2, 2025. https://www.biospectrumasia.com/analysis/122/26700/navigating-manufacturing-infrastructure-regulatory-hurdles-in-car-t-cell-therapy-growth.html
7. BioProcess International. "Dressed for success: Preparing for bottlenecks when scaling cell therapies during manufacturing." August 19, 2025. https://www.bioprocessintl.com/upstream-downstream-processing/dressed-for-success-preparing-for-bottlenecks-when-scaling-cell-therapies
8. Cellares. "Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy." January 8, 2026. https://www.cellares.com/news/cellares-and-city-of-hope-to-automate-manufacturing-of-solid-tumor-car-t-cell-therapy/
9. GEN News. "CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients." April 2026. https://www.genengnews.com/topics/bioprocessing/car-t-cell-therapy-biomanufactured-by-cellares-infused-into-first-two-patients/
10. Drug Discovery Trends. "Cellares raises $257M Series D to automate cell therapy manufacturing." February 2, 2026. https://www.drugdiscoverytrends.com/cellares-raises-257m-series-d-to-automate-cell-therapy-manufacturing/
11. ScienceDirect. "Automated manufacturing of cell therapies." February 22, 2025. https://www.sciencedirect.com/science/article/pii/S0168365925001701
12. BioProcess International. "The Make or Buy Decision for Cell and Gene Therapy Manufacturing." March 28, 2025. https://www.bioprocessintl.com/cell-therapies/the-make-or-buy-decision-for-cell-and-gene-therapy-manufacturing-implications-for-overcoming-manufacturing-bottlenecks-and-challenges
13. Forge Biologics. "AAV Manufacturing for Gene Therapy." December 12, 2025. https://www.forgebiologics.com/custom-aav-manufacturing/
14. BioSpace. "AI-Powered Cell and Gene Therapy Manufacturing Market Outlook 2034." December 4, 2025. https://www.biospace.com/press-releases/ai-powered-cell-and-gene-therapy-manufacturing-market-outlook-2034-scaling-advanced-therapies-with-digital-innovation
15. Precedence Research. "Automation, Digitization and Robotics in Cell and Gene Therapy Manufacturing Market Forecast and Outlook." April 2026. https://www.precedenceresearch.com/press-release/automation-digitization-and-robotics-in-cell-and-gene-therapy-manufacturing-market
16. AGC Bio. "Trends Shaping the Future of Cell and Gene Therapy Manufacturing." October 29, 2025. https://www.agcbio.com/biopharma-blog/trends-shaping-the-future-of-cell-and-gene-therapy-manufacturing
17. Cellular Origins. "Constellation: Flexible, scalable cell therapy manufacturing platform." January 9, 2025. https://cellularorigins.com/cell-therapy-manufacturing/
18. Frontiers in Medicine. "Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products." July 4, 2025. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1591751/full
19. Outsourced Pharma. "Contract Manufacturing Outsourcing Trends For Advanced Therapies In 2025 And Beyond." September 4, 2025. https://www.outsourcedpharma.com/doc/contract-manufacturing-outsourcing-trends-for-advanced-therapies-in-and-beyond-0001
20. Applied Cells. "The future of Point-of-Care (PoC) manufacturing: bringing cell therapies closer to the patient." August 12, 2025. https://appliedcells.com/future-of-point-of-care/
21. JCO Global Oncology. "Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico." 2025. https://ascopubs.org/doi/10.1200/GO-24-00581

About The Author:

Kien Tran holds a Ph.D. in molecular genetics & developmental biology from the University of Pittsburgh School of Medicine. She has spent a decade of her career driving scientific solutions in cell and gene therapy manufacturing and biologics development. She has led cross-functional R&D projects at both industry and academic organizations, including Cellino Biotech and Magee-Womens Research Institute, focusing on GMP-compatible workflows, process optimization, and translating complex biological systems into scalable production platforms. As founder of KT Biosync Consulting, she advises biotech clients on assay development, laboratory operations, and commercialization strategy.